MaxCyte (MXCT) Corporate presentation summary

Business overview and market opportunity

• Provides scalable, non-viral cell engineering solutions for cell and gene therapy developers, supporting 29 SPL customers and 13 clinical/commercial therapies as of June 2026.

• Addresses genetic diseases, solid tumors, infectious diseases, hematological malignancies, and autoimmune diseases.

• Ex-vivo cell and gene therapy market includes over 750 programs across research, preclinical, clinical, and commercial stages, with a focus on non-viral approaches.

• Supported by a robust IP portfolio with over 200 granted patents and 100+ pending worldwide.

• Key partnerships include a multi-platform license with Genentech, enabling broad adoption across their cell therapy portfolio.

Technology and solutions

• Expert™ platform enables high-efficiency, high-viability electroporation for cell engineering, scalable from 75,000 to 200 billion cells.

• Platform supports a wide range of gene editing tools, including CRISPR, ARCUS, TALENs, ZFNs, and RNA-based engineering.

• Integrated into closed cGMP workflows, agnostic to cell type and gene manipulation technology.

• Offers SeQure.Dx editing assessment services for on- and off-target risk analysis, aligning with FDA guidance.

• Provides comprehensive support from discovery through commercialization, including regulatory and scientific expertise.

Business model and partnerships

• Generates recurring revenue through instrument sales, single-use disposables, annual license fees, clinical milestones, and royalties.

• Strategic Platform License (SPL) model enables economic participation in partner success, with 29 active SPL partners and 12 clinical programs.

• Enterprise partnerships, such as with Genentech, provide portfolio-wide access and earlier monetization opportunities.

• SPL portfolio includes 14 active clinical trials and one commercial program (CASGEVY® for SCD and TDT).

• Significant pre-commercial milestone potential (~$110M) and over $30M in milestone payments to date.